<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.3390/jcm9051526</dc:identifier><dc:language>eng</dc:language><dc:creator>Laredo, Viviana</dc:creator><dc:creator>Sostres, Carlos</dc:creator><dc:creator>Garcia, Sandra</dc:creator><dc:creator>Carrera-Lasfuentes, Patricia</dc:creator><dc:creator>Revilla-Marti, Pablo</dc:creator><dc:creator>Lanas, Ángel</dc:creator><dc:title>No differences in gastrointestinal bleeding risk among clopidogrel-, ticagrelor-, or prasugrel-based dual antiplatelet therapy</dc:title><dc:identifier>ART-2020-118738</dc:identifier><dc:description>The risk for gastrointestinal bleeding from dual antiplatelet therapy (DAPT) with new antiplatelets (prasugrel/ticagrelor) compared to clopidogrel is unclear. Aim: To determine the risk and type of major (gastrointestinal bleeding requiring hospitalization) and minor (anemia and iron deficiency) gastrointestinal events with different types of DAPT. Methods: Retrospective observational cohort study of patients who started DAPT after percutaneous coronary intervention. Follow-up was censored after 12 months of DAPT, when a major gastrointestinal event occurred, or when DAPT was discontinued. Results: Among 1, 327 patients (54.03% were treated with clopidogrel-based DAPT, 38.13% with ticagrelor-based DAPT, and 7.84% with prasugrel-based DAPT), 29.5% had at least one gastrointestinal event. Patients taking clopidogrel-DAPT were older, with more comorbidities, and higher gastrointestinal risk compared to those taking other DAPT regimens. Adjusted hazard ratios (HRs) showed no between-group differences in the risk for major (clopidogrel vs. new antiplatelets: HR 0.996; 95% confidence interval 0.497-1.996) and minor (HR 0.920; 0.712-1.189) gastrointestinal events. Most patients received proton pump inhibitors while on DAPT (93.3%) and after withdrawal (83.2%). Conclusion: Prasugrel- or ticagrelor-based DAPT was not associated with increased gastrointestinal bleeding risk when compared to clopidogrel-DAPT. New antiplatelets do not necessarily need to be restricted to patients with low gastrointestinal risk.</dc:description><dc:date>2020</dc:date><dc:source>http://zaguan.unizar.es/record/95077</dc:source><dc:doi>10.3390/jcm9051526</dc:doi><dc:identifier>http://zaguan.unizar.es/record/95077</dc:identifier><dc:identifier>oai:zaguan.unizar.es:95077</dc:identifier><dc:identifier.citation>JOURNAL OF CLINICAL MEDICINE 9, 5 (2020), 1526  [10 pp.]</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>